Gland B2B Business Model and Growth Strategy
Near Term Focus Areas
Focus on achieving a diverse product mix offering products at various stages of their
lifecycle as well as a robust product pipeline
Operational integration of biologics facility into Gland and additional capability building on
vaccine drug substance manufacturing. We also look to continuing investments towards creating
robust infrastructure for the vaccine and bio-similar space
10
10
Expanding development and manufacturing capabilities in new delivery systems such as pens
and cartridges
Expanding development and manufacturing capabilities in complex injectables such as
peptides, long-acting injectables, suspensions and hormonal products
Geographic expansion in to emerging markets to diversify revenue base while maintaining
healthy profitability
GLANDView entire presentation